Anticoagulant Market Spoiled By Choice? Cost May Be True Differentiator

Clarity on payer responses to controversial vaccine recommendations from the Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices may be coming.

Legal experts warn, however, that new Mexican procurement rules are discriminatory and could be challenged in the courts.

The Trump Administration’s rhetoric and policy approaches illustrate the confusion that often arises between efforts to cut drug prices and cutting spending.

Companies with significant exposure to Medicare and Medicaid have fewer options for passing along higher costs to consumers because of price controls in the programs.